Hims & Hers shares rise as company adds new weight-loss medications to platform

The Hims app arranged on a smartphone in New York on Feb. 12, 2025. Hims & Hers Health shares closed up 5% on Tuesday after the company announced patients can access Eli Lilly 's weight loss medication Zepbound and diabetes drug Mounjaro, as well as the generic injection liraglutide, through its platform. Zepbound, Mounjaro and liraglutide are part of the class of weight loss medications called GLP-1s, which have exploded in popularity in recent years. Hims & Hers launched a weight loss program in late 2023, but its GLP-1 offerings have evolved as the company has contended with a volatile supply and regulatory environment. Lilly's weekly injections Zepbound and Mounjaro will cost patients $1,899 a month, according to the Hims & Hers website. The generic liraglutide will cost $299 a month, but it requires a daily injection and can be less effective than other GLP-1 medications. "As we look ahead, we plan to continue to expand our weight loss offering to deliver an even more holistic ... Read full article.